Therapeutic antibody development company Patrys (ASX:PAB) has announced new data from non-clinical studies have confirmed its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross the blood-brain barrier (BBB) in an animal model of primary brain cancer (glioblastoma multiforme, GBM).
The company said previous studies it conducted with collaborators have shown that PAT-DX1, a deoxymab antibody fragment, is able to cross the BBB in animal models of both primary and secondary brain cancer where it reduces tumour volume and increases survival.
It said this is the first time it has been shown that the full-size deoxymab, PAT-DX3, is also able to cross the BBB. Prior to this data, it had not been established whether the larger size of PAT-DX3 would limit its ability to cross the BBB.
Patrys said it intends to follow up with studies to compare the effects of both PAT-DX3 and PAT-DX1 on tumour reduction and survival in a range of primary and secondary brain cancer models. It said it is also testing PAT-DX3 as a targeting antibody for antibody-drug conjugates (ADCs) to allow the delivery of various therapeutic payloads.
CEO and managing director Dr James Campbell said: “We are very excited by this new discovery that opens up a range of development and partnering opportunities for Patrys around PAT-DX3. As PAT-DX3 shares a common mechanism of action with PAT-DX1, it is expected that it will also localise to both primary and secondary tumours in the brain and selectively kill cancer cells by blocking their DNA Damage Repair (DDR) systems. While Patrys remains focused on preparing for its first-in-human study of PAT-DX1, it is clear that PAT-DX3 is a valuable addition to the Company’s deoxymab antibody platform.”